share_log

Roth MKM Reiterates Buy on First Wave BioPharma, Maintains $11 Price Target

Benzinga ·  Sep 19, 2023 09:23

Roth MKM analyst Jonathan Aschoff reiterates First Wave BioPharma (NASDAQ:FWBI) with a Buy and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment